The effect of intravenous L-carnitine supplementation during oxaliplatin based chemotherapy on blood- and urinary levels of carnitine
- Conditions
- Carnitine metabolisme, excretie, deficiëntie, interactie met chemotherapie (oxaliplatin)Deficiency/lack of/reduction of concentration of carnitine (an amino acid or half-vitamin) during/caused by treatment with chemotherapy (oxaliplatin)10013317
- Registration Number
- NL-OMON48693
- Lead Sponsor
- Maxima Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
1. Written informed consent
2. Age >18 years
3. Start treatment with oxaliplatin-based chemotherapy
4. Understanding the Dutch language
1. No written informed consent
2. Patients with known primary carnitine deficiency (congenital)
3. Patients on haemodialysis or peritoneal dialysis
4. Patients with epilepsy
5. Current treatment with valproic acid or zidovudine
6. Current use of carnitine supplements or use of carnitine supplements
in the past 3 months
7. Pre-existent neuropathy or comorbid disorder causing neuropathy
8. Previous treatment with neurotoxic chemotherapy
9. Participation in an intervention study on CIPN (e.g. Frozen Gloves)
6. Current use of carnitine supplements or use of carnitine supplements in the
past 3 months, 7. Pre-existent neuropathy or comorbid disorder causing
neuropathy, 8. Previous treatment with neurotoxic chemotherapy, 9.
Participation in an intervention study on CIPN (e.g. Frozen Gloves)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The entire carnitine spectrum in plasma will be measured using a precursor ion<br /><br>scan. Urinary analysis will be done to measure the concentration of L-carnitine<br /><br>in urine.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable. </p><br>